Medpace Holdings, Inc.
MEDPAPI behind this page
MEDP Q1 2026 request
Playground key active
/api/financials?ticker=MEDP&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 706,604 | 558,570 | +26.5% |
Show Product Lines breakouts |
|||
| AVAI | 38,021 | 31,063 | +22.4% |
| Cardiology | 80,207 | 54,901 | +46.1% |
| Central Nervous System | 56,261 | 58,279 | -3.5% |
| Metabolic | 201,239 | 170,476 | +18.0% |
| Oncology | 237,558 | 148,015 | +60.5% |
| Other | 93,318 | 95,836 | -2.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 706,604 | 558,570 | +26.5% |
Show Counterparty Name breakouts |
|||
| CinRx Pharma and Subsidiaries · Service Agreement | 6.1 | 11.7 | -47.9% |
| LIB · Service Agreement | 1.2 | 2.2 | -45.5% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 7.3 | 13.8 | -47.1% |
| Direct Operating Costs | 510,278 | 380,220 | +34.2% |
Show Product Lines breakouts |
|||
| Direct Costs | 198,274 | 177,816 | +11.5% |
| Reimbursed out-of-pocket expenses | 312,004 | 202,404 | +54.1% |
| Reimbursed out-of-pocket expenses · Reportable Segment | 312,004 | 202,404 | +54.1% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 510,278 | 380,220 | +34.2% |
| Selling, General & Administrative | 47,917 | 57,897 | -17.2% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 47,917 | 57,897 | -17.2% |
| Depreciation | 6,751 | 6,694 | +0.9% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 6,751 | 6,694 | +0.9% |
| Amortization Of Intangible Assets | 155 | 236 | -34.3% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 155 | 236 | -34.3% |
| Total Costs & Expenses | 565,101 | 445,047 | +27.0% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 565,101 | 445,047 | +27.0% |
| Operating Income | 141,503 | 113,523 | +24.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 141,503 | 113,523 | +24.6% |
| Other Non-Operating Income (Expense) | 971 | -1,816 | +153.5% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 971 | -1,816 | +153.5% |
| Interest Income Expense Nonoperating Net | 5,117 | 6,463 | -20.8% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 5,117 | 6,463 | -20.8% |
| Non-Operating Income (Expense) | 6,088 | 4,647 | +31.0% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 6,088 | 4,647 | +31.0% |
| Income Before Taxes | 147,591 | 118,170 | +24.9% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 147,591 | 118,170 | +24.9% |
| Income Tax Expense (Benefit) | 23,721 | 3,575 | +563.5% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 23,721 | 3,575 | +563.5% |
| Net Income | 123,870 | 114,595 | +8.1% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 123,870 | 114,595 | +8.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 123,870 | 114,595 | +8.1% |
| EPS (Basic) | 4.35 | 3.77 | +15.4% |
| EPS (Diluted) | 4.28 | 3.67 | +16.6% |
| Wtd Avg Shares (Basic) | 28,445 | 30,387 | -6.4% |
| Wtd Avg Shares (Diluted) | 28,962 | 31,196 | -7.2% |
| Comprehensive Income | 121,655 | 117,717 | +3.3% |
| Labor And Related Expense (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Direct Costs · Reportable Segment | 164,603 | 143,927 | +14.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 652,681 | 441,436 | +47.9% |
| Receivables Net Current | 394,581 | 298,217 | +32.3% |
Show Counterparty Name breakouts |
|||
| CinRx Pharma and Subsidiaries · Service Agreement | 1.6 | 1.3 | +23.1% |
| LIB · Service Agreement | 1.5 | 1.5 | 0.0% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 3.1 | 2.8 | +10.7% |
| Prepaid Expenses & Other Current Assets | 91,793 | 81,784 | +12.2% |
| Total Current Assets | 1,139,055 | 821,437 | +38.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 136,548 | 128,332 | +6.4% |
| Operating Lease Right-of-Use Assets | 126,812 | 129,859 | -2.3% |
Show Counterparty Name breakouts |
|||
| Chief Executive Officer And Immediate Family · Building | 3.6 | 5.9 | -39.0% |
| Chief Executive Officer And Immediate Family · Office Space | 47.9 | 49.7 | -3.6% |
Show Related Party Transaction breakouts |
|||
| Leased Real Estate · Chief Executive Officer | 15.3 | 17.2 | -11.0% |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 59,914 | 57,083 | +5.0% |
| Related Party | 66,898 | 72,776 | -8.1% |
| Goodwill | 662,396 | 662,396 | 0.0% |
| Deferred Tax Assets | 3,220 | 99,692 | -96.8% |
| Other Non-Current Assets | 28,317 | 21,523 | +31.6% |
| Total Assets | 2,129,613 | 1,897,369 | +12.2% |
| Intangible Assets | 1,619 | 2,484 | -34.8% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 33,265 | 34,130 | -2.5% |
| Current Liabilities | |||
| Accounts Payable | 34,429 | 61,318 | -43.9% |
Show Related Party Transaction breakouts |
|||
| Travel Services · Related Party | 0.1 | 0.2 | -50.0% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 0.2 | 0.3 | -33.3% |
| Accrued Liabilities | 406,059 | 286,099 | +41.9% |
| Deferred Revenue (Current) | 856,344 | 718,716 | +19.1% |
Show Counterparty Name breakouts |
|||
| CinRx Pharma and Subsidiaries · Service Agreement | 5.6 | 5.8 | -3.4% |
| LIB · Service Agreement | 8.1 | 9.7 | -16.5% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 13.7 | 15.5 | -11.6% |
| Other Liabilities Current | 48,182 | 56,178 | -14.2% |
| Total Current Liabilities | 1,345,014 | 1,122,311 | +19.8% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 122,256 | 126,660 | -3.5% |
Show Counterparty Name breakouts |
|||
| Chief Executive Officer And Immediate Family · Building | 1.3 | 3.6 | -63.9% |
| Chief Executive Officer And Immediate Family · Building | 0.3 | 1.3 | -76.9% |
| Chief Executive Officer And Immediate Family · Office Space | 59.7 | 61.6 | -3.1% |
Show Related Party Transaction breakouts |
|||
| Leased Real Estate · Chief Executive Officer | 14.2 | 16.1 | -11.8% |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 46,764 | 44,096 | +6.1% |
| Related Party | 75,492 | 82,564 | -8.6% |
| Deferred Tax Liabilities | 3,925 | 1,838 | +113.5% |
| Other Non-Current Liabilities | 60,104 | 52,951 | +13.5% |
| Total Liabilities | 1,531,299 | 1,303,760 | +17.5% |
| Stockholders' Equity | |||
| Common Stock | 286 | 298 | -4.0% |
| Treasury Stock Common Value | -12,156 | -12,235 | +0.6% |
| Additional Paid In Capital Common Stock | 953,416 | 886,883 | +7.5% |
| Retained Earnings | -336,111 | -269,716 | -24.6% |
| Accumulated Other Comprehensive Income | -7,121 | -11,621 | +38.7% |
| Total Stockholders' Equity | 598,314 | 593,609 | +0.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -7,121 | -11,621 | +38.7% |
| Additional Paid In Capital | 953,416 | 886,883 | +7.5% |
| Common Stock | 286 | 298 | -4.0% |
| Retained Earnings | -336,111 | -269,716 | -24.6% |
| Treasury Stock Common | -12,156 | -12,235 | +0.6% |
| Total Liabilities & Equity | 2,129,613 | 1,897,369 | +12.2% |
| Treasury Stock Common Shares | 69,623 | 70,073 | -0.6% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 4,918 | 16,892 | -70.9% |
Show Income Statement Location breakouts |
|||
| Selling General And Administrative Expenses | 1,917 | 13,865 | -86.2% |
| Total Direct Costs | 3,001 | 3,027 | -0.9% |
| Operating Lease Right Of Use Asset Amortization Expense | 5,849 | 6,064 | -3.5% |
| Deferred Income Taxes | 18,543 | 749 | +2375.7% |
| Other Non-Cash Items | 400 | -502 | +179.7% |
| Increase Decrease In Receivables | 7,822 | -2,069 | +478.1% |
| Change in Prepaid & Other Assets | -1,795 | -17,553 | +89.8% |
| Change in Accounts Payable | 84 | 10,720 | -99.2% |
| Increase Decrease In Accrued Liabilities | -1,300 | -23,160 | +94.4% |
| Change in Deferred Revenue | 1,954 | 8,131 | -76.0% |
| Increase Decrease In Operating Lease Liability | -5,294 | -6,548 | +19.2% |
| Increase Decrease In Other Operating Capital Net | -10,169 | 11,587 | -187.8% |
| Net Cash from Operations | 151,788 | 125,836 | +20.6% |
| Investing Activities | |||
| Capital Expenditures | -6,814 | -9,994 | +31.8% |
| Other Investing Activities | 66 | 7 | +842.9% |
| Net Cash from Investing | -6,748 | -9,987 | +32.4% |
| Financing Activities | |||
| Proceeds From Stock Options Exercised | 12,670 | 25,934 | -51.1% |
| Net Cash from Financing | 12,670 | -345,966 | +103.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -2,078 | 2,117 | -198.2% |
| Net Change in Cash | 155,632 | -228,000 | +168.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 652,681 | 441,436 | +47.9% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.